Advertisement

 

 

Prescription of Pneumocystis Jiroveci Pneumonia Prophylaxis in HIV-Infected Patients.

Prescription of Pneumocystis Jiroveci Pneumonia Prophylaxis in HIV-Infected Patients.
Author Information (click to view)

Lin X, Garg S, Mattson CL, Luo Q, Skarbinski J,


Lin X, Garg S, Mattson CL, Luo Q, Skarbinski J, (click to view)

Lin X, Garg S, Mattson CL, Luo Q, Skarbinski J,

Advertisement
Share on FacebookTweet about this on TwitterShare on LinkedIn

Journal of the International Association of Providers of AIDS Care 2016 9 14() pii

Abstract

The US treatment guidelines recommend Pneumocystis jiroveci pneumonia (PCP) prophylaxis for all HIV-infected persons with a CD4 count <200 cells/mm(3) (ie, eligible for PCP prophylaxis). However, some studies suggest PCP prophylaxis may be unnecessary in virally suppressed patients. Using national data of HIV-infected adults receiving medical care in the United States during 2009 to 2012, the authors assessed the weighted percentage of eligible patients who were prescribed PCP prophylaxis and the independent association between PCP prophylaxis prescription and viral suppression. Overall, 81% of eligible patients were prescribed PCP prophylaxis. Virally suppressed eligible patients were less likely to be prescribed PCP prophylaxis (prevalence ratio: 0.84; 95% confidence interval: 0.80-0.89). Although guidelines recommend PCP prophylaxis for all eligible patients, some HIV care providers might not prescribe PCP prophylaxis to virally suppressed patients. Additional data on the risk for PCP among virally suppressed patients are needed to clarify this controversy.

Submit a Comment

Your email address will not be published. Required fields are marked *

2 × 3 =

[ HIDE/SHOW ]